arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

TALPHERA, INC.

TLPH
$1.01 ▼ -0.04 (-3.33%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
71 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

TALPHERA, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $76.3M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -21.5% ↘
FCF / Share $-0.05 ↘
Trailing P/E —
Price / Book 3.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

71-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-2.56M
↑ +1.4% —
Operating Margin Operating profit as % of sales
-463.6%
↓ -98.4% —
FCF / Share Free cash flow per share
$-0.05
↓ -6.7% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
11
Cash Quality ↓
53

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 21 years · 71 quarters